Home
Storia in 1 fonti
Novartis CEO: We're never done with M&A
Vas Narasimhan, CEO of pharmaceuticals company, Novartis, discusses the company's latest $12 billion acquisition of Avidity Biosciences, and ongoing negotiations with the U.S. administration over potential pharmaceuticals tariffs.
Raccontata da
cnbc.com
- ·
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
- ·
Novartis CEO: We're never done with M&A
Vas Narasimhan, CEO of pharmaceuticals company, Novartis, discusses the company's latest $12 billion acquisition of Avidity Biosciences, and ongoing negotiations with the U.S.…
- ·
Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done'
Novartis "can never be done" when it comes to major acquisitions in its sector, CEO Vas Narasimhan told CNBC.